The keynote is scheduled for 10:30 a.m. PT on Jan. 12 at the Marines’ Memorial Club in San Francisco.
Two top executives from NRx Pharmaceuticals and its subsidiary HOPE Therapeutics will present the keynote address at the 8th Annual Neuroscience Innovation Forum in San Francisco, the company said.
Jonathan Javitt, founder and CEO of NRx Pharmaceuticals and co-CEO of HOPE Therapeutics, and David Feifel, chief medical innovation officer of HOPE and founder of the Kadima Neuropsychiatry Institute, will deliver a keynote entitled “Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD.”
The keynote is scheduled for 10:30 a.m. PT on Jan. 12 at the Marines’ Memorial Club in San Francisco.
They also will be available for one-on-one meetings with investors and partners at the meeting and the JPM Healthcare Conference, the company said.
Forum on January 12, 2025, at the Marines’ Memorial Club in San Francisco at 10:30am PT.
“The keynote will focus on the integration of NMDA-targeted drug therapy such as ketamine with other emerging modalities such as transcranial magnetic stimulation (TMS) and digital therapeutics to produce synergistic therapeutic effects that will permanently alter the clinical trajectory of patients with suicidal depression, PTSD and other debilitating neuropsychiatric conditions for which there is a great need for better treatments,” the company explained in a news release.
“Although the introduction of ketamine for these and other indications has been a medical breakthrough, intravenous ketamine alone is not sufficiently efficacious for many patients, and may not create a sufficiently durable response for many for whom it is highly efficacious. Recent data suggest that the integration of ketamine with other emerging neuromodulation, pharmacologic and digital therapeutics may be key to inducing improvements that are sufficiently strong and durable to allow all patients who suffer from suicidal depression and PTSD lead productive and rewarding lives.”
The Sachs Forum, held annually during the JP Morgan Healthcare Conference week, brings together leaders and innovators in neuroscience to explore cutting-edge advancements in therapeutics, neurotechnology and diagnostics.
Feifel, HOPE’s newly designated chief medical innovation officer, “has been a pioneer and international thought leader for advanced interventional treatment of psychiatric disorders such as depression, anxiety, PTSD and related disorders for more than three decades,” according to the company.